Impact of the COVID-19 pandemic on visual outcomes of diabetic macular edema patients at a tertiary care veterans affairs center

[1] Cheung N(2010)Diabetic retinopathy Lancet 376 124-136

[2] Mitchell P(2012)Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 556-564

[3] Wong TY(2003)Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies Diabetes Care 26 2653-2664

[4] Yau JWY(2014)Anti-vegf therapy for diabetic macular edema Curr Diab Rep 14 510-2017

[5] Rogers SL(2020)The impact of the covid-19 pandemic on hospital admissions in the united states Health Aff 39 2010-434

[6] Kawasaki R(2020)Real-world vitreoretinal practice patterns during the 2020 COVID-19 pandemic: a nationwide, aggregated health record analysis Curr Opin Ophthalmol 31 427-795

[7] Ciulla TA(2016)Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study Br J Ophthalmol 100 787-733

[8] Amador AG(2020)Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic Int J Retina Vitreous 6 20-S15

[9] Zinman B(2021)Short term visual and structural outcomes of anti-vascular endothelial growth factor (Anti-vegf) treatment delay during the first COVID-19 wave: A pilot study PLoS One 16 730-160

[10] Stewart MW(2021)Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown Indian J Ophthalmol 69 S9-18

[1] Cheung N(2010)Diabetic retinopathy Lancet 376 124-136

[2] Mitchell P(2012)Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 556-564

[3] Wong TY(2003)Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies Diabetes Care 26 2653-2664

[4] Yau JWY(2014)Anti-vegf therapy for diabetic macular edema Curr Diab Rep 14 510-2017

[5] Rogers SL(2020)The impact of the covid-19 pandemic on hospital admissions in the united states Health Aff 39 2010-434

[6] Kawasaki R(2020)Real-world vitreoretinal practice patterns during the 2020 COVID-19 pandemic: a nationwide, aggregated health record analysis Curr Opin Ophthalmol 31 427-795

[7] Ciulla TA(2016)Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study Br J Ophthalmol 100 787-733

[8] Amador AG(2020)Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic Int J Retina Vitreous 6 20-S15

[9] Zinman B(2021)Short term visual and structural outcomes of anti-vascular endothelial growth factor (Anti-vegf) treatment delay during the first COVID-19 wave: A pilot study PLoS One 16 730-160

[10] Stewart MW(2021)Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown Indian J Ophthalmol 69 S9-18